Press

With biotech venture funding far tighter than it was in the 2021 boom, early-stage companies are learning a hard truth: capital alone does not de-risk drug development. Leen Kawas argues that in today’s market, operational expertise, strategic guidance, and high-leverage networks are what keep promising science alive between long funding cycles. Using Propel Bio Partners’ venture partner model, including the appointment of seasoned operator Laurie Heilmann, she lays out why l

Leen Kawas argues that biotech leadership is less about certainty and more about staying steady inside the unknown. For her, motherhood became an unplanned training ground for exactly that: tolerating ambiguity, reading what is not said, thinking in long timelines, and staying purpose-driven through setbacks that do not resolve quickly. She connects the daily realities of raising two young children with the realities of drug development and company building, framing caregivin

Leen Kawas argues that capital is not enough to move biotech from discovery to durable commercial success. At Propel Bio Partners, she is building an investor model that treats strategic expertise, networking, and hands-on operational guidance as core value, not extras. The appointment of healthcare technology veteran Laurie Heilmann as Venture Partner illustrates what that looks like in practice: embedded support on commercialization strategy, market expansion, partnerships,

Leen Kawas believes a therapy that cannot reach the patients who need it is not a true breakthrough. As Managing General Partner at Propel Bio Partners, she evaluates biotech through a third lens beyond novelty and market size: accessibility for underserved populations. This approach shows up in how companies design studies, build diagnostics, and deploy tools that work outside elite healthcare settings, from mail-in microbiome research to faster, lower-infrastructure testing

Propel Bio Partners has named healthcare technology veteran Laurie Heilmann as a Venture Partner, adding a commercialization operator with decades of experience across diagnostics, drug development, and medical devices. Heilmann is known for taking companies from early build to scale, including leading Crown Bioscience through its exit to JSR Life Sciences, plus board and executive roles across the sector. Managing General Partner Leen Kawas says the hire strengthens Propel B

Leen Kawas shares the personal story that pushed her into biotech, from growing up in Amman to building and taking a company public, then shifting into venture as a co-founder of Propel Bio Partners. In this Q&A she talks candidly about early mistakes, what she is building now, and where she thinks AI actually helps life sciences versus where it falls short. She also lays out her framework for deciding when to use AI and when humans must stay in the lead, and ends with a bigg

Most VC in biotech still runs like a transaction: fund the science, take a board seat, check in quarterly. Leen Kawas argues that model is built for software, not drug development. This article breaks down her “ecosystem” approach to investing, why scientists often struggle with the networking side of building a company, and how founders can use advisory boards, conferences, and even non-investing VCs as strategic infrastructure. The takeaway is practical: in biotech, the rig

Most biotech companies hunt for advantage in patents, pipelines, and platforms. Leen Kawas argues one of the biggest differentiators is simpler: who is in the room making decisions. This article lays out the performance case for diverse leadership, why different lived and business experience changes strategy and execution, and how those benefits compound over time, from stronger cultures and retention to better stakeholder trust. It also looks ahead to an AI-heavy future, whe

Biotech doesn’t have to cost hundreds of millions to get off the ground. This article follows Leen Kawas’s argument that the industry’s biggest problem isn’t science, it’s redundancy: expensive habits that stuck around because “that’s how it’s always done.” It breaks down where those inefficiencies hide, how founders can use technology (including AI) to streamline workflows without cutting corners, and what “capital-efficient” drug development actually looks like in practice

Biotech is no longer just a scientist’s domain. This article explores how Leen Kawas—pharmacist turned entrepreneur and now Managing General Partner at Propel Bio Partners—is reshaping the industry’s leadership model. From AI-powered drug development to patient-centric clinical trials, Kawas champions a multidisciplinary approach that prioritizes efficiency, empathy, and innovation. Drawing on insights relevant to founders, investors, and thought leaders like Tanner Winterhof

Leen Kawas doesn’t talk about women in biotech as a feel-good story. She argues it is a performance edge. This piece opens with her 2020 IPO milestone, then makes the case that female leadership is uniquely positioned for where life sciences is headed right now: trial diversity pressure, patient-centric development, and capital efficiency. You’ll see how Kawas connects leadership mix to measurable outcomes, why different lived experience can surface overlooked markets, and wh

Leen Kawas' journey from pharmacy student to biotech investor reveals how female founders navigate entrenched bias to drive breakthrough innovation. As Managing General Partner at Propel Bio Partners, Kawas invests in companies led by diverse, mission-driven teams focused on patient-first innovation. Her leadership philosophy centers on inclusivity, practical problem-solving, and elevating overlooked markets—principles she practiced while co-founding Athira and continues to c

Leen Kawas, Managing General Partner at Propel Bio Partners, is challenging the geographic and demographic concentration of biotech innovation. While California and Massachusetts receive nearly 70% of U.S. biotech funding, Kawas focuses on underserved regions and populations, investing in companies like Inherent Biosciences, Persephone Biosciences, and OmniVis. These firms are developing equitable solutions across male infertility, infant gut health, and global disease detect

Leen Kawas, Managing General Partner at Propel Bio Partners, is reshaping biotech investing through a strategy grounded in health equity and inclusive innovation. In response to the stark disparities in clinical trial representation, treatment access, and affordability, Kawas advocates for intentional innovation—backing companies that prioritize underserved populations globally. From Persephone Biosciences’ microbiome research for infant health to Inherent Biosciences’ epigen

In this episode of the Top Entrepreneurs Podcast  on the Enterprise Podcast Network, Leen Kawas, Managing General Partner of Propel Bio Partners, shares her journey from scientist to investor. With a background in life sciences and a passion for innovation, Kawas now leads a venture capital firm focused on supporting entrepreneurs building biotech companies that deliver transformative health solutions. She discusses the transition from the lab to the boardroom, her vision for

In this Enterprise Radio interview, Leen Kawas—Managing General Partner of Propel Bio Partners—shares insights from her path as a scientist, biotech CEO, and now venture capital leader. She discusses how founders can translate innovation into successful businesses, the importance of investor alignment in high-risk sectors like biotech, and how leaders can create value beyond funding. Kawas also explores balancing scientific rigor with entrepreneurial speed, mentoring women in

The biotechnology investment landscape has fundamentally changed. Traditional drug discovery timelines that stretch 8-10 years from...

Most venture capitalists have never walked in an entrepreneur’s shoes. They’ve built careers evaluating companies from the outside, armed...

The transition from scientist to CEO represents one of the most challenging career pivots in biotechnology. Brilliant researchers who can...

Here’s a statistic that might surprise you: women make up about half of the biotechnology workforce, but they hold only 30 percent of...